Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate whether perioperative pregabalin, compared with placebo, reduces persistent postsurgical pain and improves functional disability and health-related quality of life 3 months or more after lumbar spine surgery in adults. METHODS: PubMed/MEDLINE, Embase, and CENTRAL were searched for placebo-controlled randomized controlled trials of perioperative gabapentinoids in adults undergoing elective lumbar spine surgery with a minimum follow-up of three months (PROSPERO CRD420261401910). The primary outcome was pain intensity at 3 months. Sufficiently homogeneous outcomes were pooled with random-effects meta-analyses (restricted maximum likelihood), and robustness was assessed with leave-one-out analyses; health-related quality of life was synthesized narratively. Risk of bias was assessed with RoB 2 and certainty of evidence with GRADE. RESULTS: Five randomized controlled trials (335 participants) were included, all evaluating pregabalin. Pregabalin did not reduce pain intensity at 3 months (4 trials, 275 participants; standardized mean difference [SMD] 0.03, 95% confidence interval [CI] -0.41 to 0.47; I² = 69%; low certainty) or at the latest follow-up (SMD -0.13, 95% CI - 0.59 to 0.32; I² = 73%). Functional disability was lower with pregabalin (2 trials, 143 participants; SMD -0.51, 95% CI - 0.86 to - 0.16), but the differences were below minimal important change thresholds (very low certainty). Health-related quality of life (two trials, non-equivalent instruments) was synthesized narratively; early differences favoring pregabalin were not sustained at 1 year. In an exploratory analysis of four trials, a favorable functional outcome was more frequent with pregabalin (risk ratio 1.44, 95% CI 1.11 to 1.86; very low certainty). Adverse events were inconsistently reported. CONCLUSIONS: In adults undergoing lumbar spine surgery, low-certainty evidence suggests that perioperative pregabalin results in little to no difference in pain intensity 3 months after surgery. Evidence on functional disability and quality of life is limited to few small trials and is very uncertain. Adequately powered trials enrolling patients at high risk of persistent postsurgical pain, with standardized outcomes and systematic reporting of harms, are needed.
No takes yet. Share an insight, caveat, or question.
Correia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: